Medicines related to Valproate: Risk of abnormal pregnancy outcomes

Date published: 02 February 2015

This letter is to inform you of important new information and strengthened warnings related to safety of medicines related to valproate (sodium valproate, valproic acid [brand leader: Epilim] and valproate semisodium [brand leader: Depakote]), following completion of a Europe-wide review. 

Back to top